Drug Trial Radar · NCT03334617
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
528
Actual
Start
Dec 18, 2017
Primary completion
Sep 13, 2024
Study completion Sep 11, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Conditions
- Non-Small Cell Lung Cancer
Interventions
DurvalumabDrug
Participants will receive IV infusion of durvalumab as stated in arm description.
DanvatirsenDrug
Participants will receive IV infusion of danvatirsen as stated in arm description.
CeralasertibDrug
Participants will receive oral tablet of ceralasertib as stated in arm description.
VistusertibDrug
Participants will receive oral tablets of vistusertib as stated in arm description.
OlaparibDrug
Participants will receive oral tablets of olaparib as stated in arm description.
OleclumabDrug
Participants will receive IV infusion of oleclumab as stated in arm description.
Trastuzumab deruxtecanDrug
Participants will receive IV infusion of trastuzumab deruxtecan as stated in arm description.
CediranibDrug
Participants will receive oral tablets of cediranib as stated in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)Time frame: Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)
Locations
45 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Fullerton, California
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Washington D.C., District of Columbia
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
Fairfax, Virginia
Research Site
Innsbruck, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Edmonton, Alberta, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Bordeaux, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Villejuif, France
Research Site
Berlin, Germany
Research Site
Esslingen a.N., Germany
Research Site
Großhansdorf, Germany
Research Site
Heidelberg, Germany
Research Site
Haifa, Israel
Research Site
Kfar Saba, Israel
Research Site
Petah Tikva, Israel
Research Site
Ramat Gan, Israel
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.